CN110833575B - A topical Chinese medicinal composition for the treatment of intestinal obstruction - Google Patents
A topical Chinese medicinal composition for the treatment of intestinal obstruction Download PDFInfo
- Publication number
- CN110833575B CN110833575B CN201810937922.3A CN201810937922A CN110833575B CN 110833575 B CN110833575 B CN 110833575B CN 201810937922 A CN201810937922 A CN 201810937922A CN 110833575 B CN110833575 B CN 110833575B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Abstract
The invention provides a traditional Chinese medicine composition for external use for treating intestinal obstruction, which is prepared from the following raw material medicines: rhizoma Ligustici Chuanxiong, Saviae Miltiorrhizae radix, Borneolum, and radix Codonopsis. Clinical experiment research results show that the total clinical effective rate of the traditional Chinese medicine composition for treating intestinal obstruction by external application is 93.3%, and abdominal distension and abdominal pain symptoms of patients with intestinal obstruction can be obviously improved.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for external use for treating intestinal obstruction, and belongs to the field of medicines.
Background
Intestinal obstruction (intestinal obstruction) is a barrier to the passage of intestinal contents caused by various causes, and has four main clinical manifestations: pain, vomiting, distention and amenorrhea are clinically common emergencies with complicated and variable conditions. The causes of the disease mainly include mechanical ileus, dynamic ileus and ischemic ileus. Although the obstruction can be relieved by the operation, the wound is large, new adhesion can be formed after the operation, and the possibility of reoccurrence of the obstruction exists.
Chinese patent CN 104491381A discloses a traditional Chinese medicine composition for treating adhesive ileus, which comprises twenty-eight raw materials of magnolia officinalis, immature bitter orange, radish seed, costustoot, combined spicebush root, green tangerine orange peel, Chinese angelica, red paeony root, peach seed, raw rhubarb, mirabilite, raw kansui root, senna leaf, safflower, tree peony bark, corydalis tuber, dangshen, dwarf lilyturf tuber, honey locust, inula flower, red sage root, szechuan lovage rhizome, liquoric root, leech, oriental waterplantain rhizome, Indian buead, rhizoma corydalis, hemp seed and the like.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide a traditional Chinese medicine composition for treating intestinal obstruction by external application.
As one aspect of the invention, the invention provides a traditional Chinese medicine composition for external use for treating intestinal obstruction, which is prepared from the following raw material medicines: rhizoma Ligustici Chuanxiong, Saviae Miltiorrhizae radix, Borneolum, and radix Codonopsis.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 6-30 parts of ligusticum wallichii, 18-60 parts of salvia miltiorrhiza, 5-22 parts of borneol and 6-30 parts of codonopsis pilosula;
further preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 9-25 parts of ligusticum wallichii, 22-45 parts of salvia miltiorrhiza, 6-18 parts of borneol and 9-25 parts of codonopsis pilosula;
or, the traditional Chinese medicine composition is prepared from the following raw material medicines: 12-20 parts of ligusticum wallichii, 26-38 parts of salvia miltiorrhiza, 8-15 parts of borneol and 12-20 parts of codonopsis pilosula;
most preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 15 parts of ligusticum wallichii, 30 parts of salvia miltiorrhiza, 10 parts of borneol and 15 parts of codonopsis pilosula;
or 13 parts of ligusticum wallichii, 36 parts of salvia miltiorrhiza, 9 parts of borneol and 18 parts of codonopsis pilosula;
or 19 parts of ligusticum wallichii, 27 parts of salvia miltiorrhiza, 14 parts of borneol and 13 parts of codonopsis pilosula.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
the raw materials are taken according to a certain proportion, crushed or extracted by water or an organic solvent according to a conventional extraction method, and prepared into an external preparation according to a conventional preparation process.
The conventional extraction method comprises any one of reflux extraction, immersion extraction, ultrasonic extraction or percolation extraction, or the combination of different extraction methods; the organic solvent is one or more of methanol, 20-95% ethanol solution and acetone. The external preparation comprises patch, cataplasma, ointment, plaster, gel, liniment, lotion, plastics, etc.
The traditional Chinese medicine composition of the invention can be prepared by adding the extracts (effective parts) of the raw medicinal materials except the red sage root, the codonopsis pilosula and the ligusticum wallichii in the form of the raw medicinal materials, so that the invention further discloses a traditional Chinese medicine composition for treating intestinal obstruction by external application:
a traditional Chinese medicine composition for external use for treating intestinal obstruction is prepared from the following raw materials: rhizoma Ligustici Chuanxiong extract, Saviae Miltiorrhizae radix extract, Borneolum Syntheticum, and radix Codonopsis extract.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 6-30 parts of ligusticum wallichii extract, 18-60 parts of salvia miltiorrhiza extract, 5-22 parts of borneol and 6-30 parts of codonopsis pilosula extract;
further preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 9-25 parts of ligusticum wallichii extract, 22-45 parts of salvia miltiorrhiza extract, 6-18 parts of borneol and 9-25 parts of codonopsis pilosula extract;
or, the traditional Chinese medicine composition is prepared from the following raw material medicines: 12-20 parts of ligusticum wallichii extract, 26-38 parts of salvia miltiorrhiza extract, 8-15 parts of borneol and 12-20 parts of codonopsis pilosula extract;
most preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines: 15 parts of ligusticum wallichii extract, 30 parts of salvia miltiorrhiza extract, 10 parts of borneol and 15 parts of codonopsis pilosula extract;
or 13 parts of ligusticum wallichii extract, 36 parts of salvia miltiorrhiza extract, 9 parts of borneol and 18 parts of codonopsis pilosula extract;
or 19 parts of ligusticum wallichii extract, 27 parts of salvia miltiorrhiza extract, 14 parts of borneol and 13 parts of codonopsis pilosula extract.
The above crude drug extract can be water extract, organic solvent extract, or refined extract obtained by further refining and purifying water extract/organic solvent extract.
The organic solvent is selected from one or more of methanol, 20-95% ethanol solution and acetone;
the extraction method for preparing the extract comprises any one of reflux extraction, immersion extraction, ultrasonic extraction or percolation extraction, or the combination of different extraction methods.
As another aspect of the invention, the invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating intestinal obstruction.
The raw material medicines of the invention, such as salvia miltiorrhiza, borneol, radix codonopsitis and rhizoma ligustici wallichii, all accord with the record of Chinese pharmacopoeia (2015 edition). In the formula, the salvia miltiorrhiza cools blood and activates blood, is monarch, the codonopsis pilosula invigorates spleen and tonifies qi, is ministerial, and the ligusticum wallichii activates blood and activates qi, is adjuvant and borneol pungent and disperses, so that the medicine can penetrate into the interior through skin and is used as a guide. The formula is concise, the effect is obvious, and the clinical experiment research result shows that the total clinical effective rate of the traditional Chinese medicine composition for treating intestinal obstruction by external application is 93.3 percent, and the traditional Chinese medicine composition can obviously improve the symptoms of abdominal distension and abdominal pain of patients with intestinal obstruction.
Detailed Description
Example 1
The formula is as follows: 15g of ligusticum wallichii, 30g of salvia miltiorrhiza, 10g of borneol and 15g of codonopsis pilosula;
the preparation method comprises the following steps: pulverizing the raw materials, adding yellow wine, and concocting into paste until the paste does not flow.
The use method comprises the following steps: applied to Shenque acupoint, and changed 1 time per day.
Example 2
The formula is as follows: 13g of ligusticum wallichii, 36g of salvia miltiorrhiza, 9g of borneol and 18g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, decocting with water twice, each for 1 hr, filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make into topical patch.
Example 3
The formula is as follows: 19g of ligusticum wallichii, 27g of salvia miltiorrhiza, 14g of borneol and 13g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding water, extracting under reflux twice (each for 1 hr), filtering, mixing filtrates, and concentrating; adding conventional adjuvants, and making into topical unguent.
Example 4
The formula is as follows: 14g of ligusticum wallichii, 34g of salvia miltiorrhiza, 8g of borneol and 16g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding 70% ethanol solution, reflux extracting for two times (each time for 1 hr), filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make topical cataplasma.
Example 5
The formula is as follows: 17g of ligusticum wallichii, 28g of salvia miltiorrhiza, 12g of borneol and 14g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding 70% ethanol solution, ultrasonic extracting twice for 40min each time, filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make topical cataplasma.
Example 6
The formula is as follows: 11g of ligusticum wallichii, 42g of salvia miltiorrhiza, 7g of borneol and 23g of codonopsis pilosula;
the preparation method comprises the following steps: pulverizing the raw materials, adding yellow wine, stirring, making into navel patch cake, and sealing in prepared patch bag.
Example 7
The formula is as follows: 23g of ligusticum wallichii, 24g of salvia miltiorrhiza, 17g of borneol and 10g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, decocting with water twice, each for 1 hr, filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make into topical patch.
Example 8
The formula is as follows: 12g of ligusticum wallichii, 40g of salvia miltiorrhiza, 6g of borneol and 21g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding water, extracting under reflux twice (each for 1 hr), filtering, mixing filtrates, and concentrating; adding conventional adjuvants, and making into topical unguent.
Example 9
The formula is as follows: 22g of ligusticum wallichii, 25g of salvia miltiorrhiza, 16g of borneol and 11g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding 70% ethanol solution, reflux extracting for two times (each time for 1 hr), filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make topical cataplasma.
Example 10
The formula is as follows: 7g of ligusticum wallichii, 55g of salvia miltiorrhiza, 5g of borneol and 28g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding 70% ethanol solution, ultrasonic extracting twice for 40min each time, filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make topical cataplasma.
Example 11
The formula is as follows: 28g of ligusticum wallichii, 20g of salvia miltiorrhiza, 21g of borneol and 7g of codonopsis pilosula;
the preparation method comprises the following steps: pulverizing the raw materials, adding yellow wine, stirring, making into navel patch cake, and sealing in prepared patch bag.
Example 12
The formula is as follows: 8g of ligusticum wallichii, 50g of salvia miltiorrhiza, 6g of borneol and 7g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, decocting with water twice, each for 1 hr, filtering, mixing filtrates, and concentrating; centrifuging at high speed, and taking supernatant; adding conventional adjuvants to make into topical patch.
Example 13
The formula is as follows: 26g of ligusticum wallichii, 21g of salvia miltiorrhiza, 20g of borneol and 8g of codonopsis pilosula;
the preparation method comprises the following steps: mixing the raw materials, adding water, extracting under reflux twice (each for 1 hr), filtering, mixing filtrates, and concentrating; adding conventional adjuvants, and making into topical unguent.
Example 14
The formula is as follows: 15g of ligusticum wallichii extract, 30g of salvia miltiorrhiza extract, 10g of borneol and 15g of codonopsis pilosula extract.
Example 15
The formula is as follows: 13g of ligusticum wallichii extract, 36g of salvia miltiorrhiza extract, 9g of borneol and 18g of codonopsis pilosula extract.
Example 16
The formula is as follows: 19g of ligusticum wallichii extract, 27g of salvia miltiorrhiza extract, 14g of borneol and 13g of codonopsis pilosula extract.
Example 17
The formula is as follows: 14g of ligusticum wallichii extract, 34g of salvia miltiorrhiza extract, 8g of borneol and 16g of codonopsis pilosula extract.
Example 18
The formula is as follows: 17g of ligusticum wallichii extract, 28g of salvia miltiorrhiza extract, 12g of borneol and 14g of codonopsis pilosula extract.
Example 19
The formula is as follows: 11g of ligusticum wallichii extract, 42g of salvia miltiorrhiza extract, 7g of borneol and 23g of codonopsis pilosula extract.
Example 20
The formula is as follows: 23g of ligusticum wallichii extract, 24g of salvia miltiorrhiza extract, 17g of borneol and 10g of codonopsis pilosula extract.
The extracts described in examples 14-20 above are water extracts of each crude drug.
EXAMPLE 21 Effect example
1. Clinical data
1.1 general data
60 patients admitted to 2016, 1 month to 2017, 1 month hospitalized patients all meet the diagnosis standard of incomplete intestinal obstruction, wherein 35 men and 25 women have the ages of 18-70 years and the course of the disease is 6-72 hours. Randomized into 2 groups: the treatment group and the control group have 30 cases respectively, and the two groups have no obvious difference in sex, age, disease course and the like.
1.2 diagnostic criteria:
the Western medicine diagnosis is drawn up according to the diagnosis standard of incomplete intestinal obstruction in the national high school textbook "surgery" of version 8:
(1) clinical symptoms: abdominal pain and abdominal distension, nausea and vomiting, anorexia, anus exhaust and defecation stopping, and the like; physical examination: a distended abdomen, even with intestinal type or intestinal peristaltic wave, a soft abdomen, pressure pain spots or percussion pain, a drum sound in percussion, and a weak and disappearing audible and hyperactive bowel sound, excessive breathing or bowel sound.
(2) Abdominal X-ray examination (the preferred method for diagnosing ileus): firstly, the intestinal canal expands to a certain extent, the inner diameter width is more than 2.5cm, fluid accumulation and qi accumulation occur, flatulence in the small intestine is not obvious, and a small amount of gas exists in the colon; secondly, a plurality of liquid-gas planes can be seen in the expanded intestinal canal, and the intestinal canal under obstruction collapses; and appearance of small intestinal mucosa or colon sack image.
1.3 inclusion criteria:
meeting the diagnosis standard of incomplete intestinal obstruction;
② people with the age of 18-65 years old, male and female are not limited;
the subject knows the consent and voluntarily signs the consent.
1.4 exclusion criteria:
firstly, the patient has malignant tumor of digestive tract;
② those with fever or using antibacterial drugs;
③ those accompanied with systemic inflammatory reaction syndrome;
fourthly, the patients with allergy to the known drugs and the patients with allergic constitution;
patients with serious cardiovascular and cerebrovascular diseases, liver and kidney diseases.
1.5 treatment regimens
Treatment groups: the conventional western medicine treatment method comprises the following steps: no appetite, continuous gastrointestinal decompression; correcting water and electrolyte disorder; maintaining acid-base balance, supporting parenteral nutrition, preventing infection, etc. ② the medicine is externally applied on the Shenque point, and the medicine composition is as follows: 15g of ligusticum wallichii, 30g of salvia miltiorrhiza, 10g of borneol and 15g of codonopsis pilosula. The above materials are ground into fine powder, blended with yellow wine into paste, applied on Shenque acupoint until no flow occurs, and sealed and fixed externally by acupoint plaster, and changed 1 time per day.
Control group: the conventional treatment of western medicine is performed in the same treatment group; ② the medicine is externally applied on the Shenque point, and the medicine composition is as follows: 20g of rheum officinale, 20g of mangnolia officinalis, 20g of immature bitter orange, 15g of radish seed, 15g of costustoot, 15g of radix paeoniae rubra and 6g of borneol. The above materials are ground into fine powder, blended with sesame oil into thick paste, applied on Shenque acupoint until no flow occurs, and sealed and fixed externally by acupoint plaster, and changed 1 time per day.
The course of treatment is as follows: the two treatment courses are 3 days.
1.6 therapeutic effect evaluation index and determination method
1.6.1 therapeutic efficacy evaluation index
Observing abdominal pain and abdominal distension degrees before and after two groups of treatments, and anus exhausting and defecation time after two groups of treatments, wherein the abdominal pain degree is selected from a Visual Analogue (VAS, Visual Analogue Scale/Score) abdominal pain Scale of 0-10 points: firstly, 0 has no pain and no abdominal pain feeling; 1-3 points, mild abdominal pain, no influence on work and life; ③ 4-6 points, moderate abdominal pain, influence work, do not influence life; 7-10 points, severe abdominal pain and severe pain affect work and life.
The degree of abdominal distension is selected from a VAS abdominal distension scale of 0-10 minutes, and the first 0 is painless and has no abdominal distension feeling; 1-3 points, slight abdominal distension, no influence on work and life; ③ 4-6 points, moderate abdominal distension, influence on work and not influence on life; and 7-10 points of severe abdominal distension and even abdominal bulge, which affect work and life.
1.6.2 therapeutic efficacy assessment criteria
The method is drawn up according to the clinical research guiding principle of the new traditional Chinese medicine:
(1) the effect is shown: the symptoms or physical signs are obviously improved, and the symptom integral is reduced by more than or equal to 70 percent.
(2) The method has the following advantages: the symptoms or physical signs are improved, and the symptom integral is reduced by more than or equal to 30 percent.
(3) And (4) invalidation: no significant improvement or even aggravation of symptoms or signs was observed, and the integral of symptoms was reduced by < 30%.
Note: the formula (nimodipine method) ═ integration before treatment-integration after treatment)/integration before treatment ] × 100% was calculated.
1.6.3 statistical treatment
Using SPSS 19.0 statistical software, the measured data is expressed by mean plus or minus standard deviation, and adopting t test; checking the counting data by a chi-square method; data that did not fit a normal distribution were examined non-parametrically.
2. Results
2.1 comparison of the degree of abdominal distension and pain before and after treatment in the two groups
The comparison of the degree of abdominal distension and abdominal pain before and after the two groups of treatments is shown in Table 1.
TABLE 1 comparison of the degree of abdominal distension and pain before and after two groups of treatment
Note: comparing before treatment by t test, wherein P is less than 0.01;▲p < 0.05 in comparison with the treated group.
The integral comparison of abdominal distension and abdominal pain before treatment of the two groups has no obvious difference (P is more than 0.05), the scores of abdominal distension and abdominal pain after treatment of the two groups are obviously reduced, the difference is obviously lower than that before treatment, and the difference has statistical significance (P is less than 0.01). The abdominal distension score of the treatment group after treatment is 1.34 +/-0.33, the abdominal distension score of the control group is 2.01 +/-0.41, the treatment group is obviously lower than the control group, and the difference has statistical significance (P is less than 0.05); the two groups of controls had significant differences in abdominal pain scores after treatment (P > 0.05).
2.2 comparison of two sets of Total efficiencies
The two groups of therapeutic effects after treatment are compared in table 2.
TABLE 2 comparison of two sets of Total efficiencies
The treatment group has 17 cases of obvious effect, 11 cases of effect and 2 cases of no effect, and the total effective rate is 93.3 percent; the control group has 12 cases of obvious effect, 15 cases of effect and 4 cases of no effect, the total effective rate is 86.7 percent, and the treatment group is obviously higher than the control group.
3. Conclusion
The Chinese medicinal acupoint application is combined with the Shenque acupoint treatment and the conventional Western medicine treatment, so that intestinal obstruction can be effectively treated, and the abdominal distension and the abdominal pain degree can be relieved. The formula of the invention is superior to the prior formula in relieving the abdominal distension caused by incomplete intestinal obstruction.
Claims (9)
1. The externally-applied traditional Chinese medicine composition for treating intestinal obstruction is characterized by being prepared from the following raw material medicines: 6-30 parts of ligusticum wallichii, 18-60 parts of salvia miltiorrhiza, 5-22 parts of borneol and 6-30 parts of codonopsis pilosula.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines: 9-25 parts of ligusticum wallichii, 22-45 parts of salvia miltiorrhiza, 6-18 parts of borneol and 9-25 parts of codonopsis pilosula.
3. The traditional Chinese medicine composition of claim 2, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines: 12-20 parts of ligusticum wallichii, 26-38 parts of salvia miltiorrhiza, 8-15 parts of borneol and 12-20 parts of codonopsis pilosula.
4. The traditional Chinese medicine composition of claim 3, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines: 15 parts of ligusticum wallichii, 30 parts of salvia miltiorrhiza, 10 parts of borneol and 15 parts of codonopsis pilosula;
or 13 parts of ligusticum wallichii, 36 parts of salvia miltiorrhiza, 9 parts of borneol and 18 parts of codonopsis pilosula;
or 19 parts of ligusticum wallichii, 27 parts of salvia miltiorrhiza, 14 parts of borneol and 13 parts of codonopsis pilosula.
5. The traditional Chinese medicine composition of any one of claims 1 to 4, wherein the traditional Chinese medicine composition is a composition prepared by crushing and mixing raw materials, or an extract prepared by mixing or extracting the raw materials separately, or an effective part prepared by further refining and purifying the extract, or a conventional preparation prepared by adding pharmaceutically acceptable auxiliary materials.
6. A traditional Chinese medicine composition for external use for treating intestinal obstruction is characterized by being prepared from the following raw materials: 6-30 parts of ligusticum wallichii extract, 18-60 parts of salvia miltiorrhiza extract, 5-22 parts of borneol and 6-30 parts of codonopsis pilosula extract.
7. The traditional Chinese medicine composition of claim 6, wherein the traditional Chinese medicine composition is prepared from the following raw materials: 9-25 parts of ligusticum wallichii extract, 22-45 parts of salvia miltiorrhiza extract, 6-18 parts of borneol and 9-25 parts of codonopsis pilosula extract.
8. The traditional Chinese medicine composition of claim 7, wherein the traditional Chinese medicine composition is prepared from the following raw materials: 15 parts of ligusticum wallichii extract, 30 parts of salvia miltiorrhiza extract, 10 parts of borneol and 15 parts of codonopsis pilosula extract.
9. The use of a Chinese medicinal composition as claimed in any one of claims 1-4, 6-8 in the preparation of a medicament for the treatment of ileus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937922.3A CN110833575B (en) | 2018-08-16 | 2018-08-16 | A topical Chinese medicinal composition for the treatment of intestinal obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937922.3A CN110833575B (en) | 2018-08-16 | 2018-08-16 | A topical Chinese medicinal composition for the treatment of intestinal obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110833575A CN110833575A (en) | 2020-02-25 |
| CN110833575B true CN110833575B (en) | 2022-02-22 |
Family
ID=69573614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810937922.3A Active CN110833575B (en) | 2018-08-16 | 2018-08-16 | A topical Chinese medicinal composition for the treatment of intestinal obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110833575B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933138A (en) * | 2021-03-05 | 2021-06-11 | 兴德堂(北京)医药研究院 | External bathing formula for intestinal obstruction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785850A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional combination and preparation method thereof for intestinal obstruction treatment |
| CN104491381A (en) * | 2014-11-24 | 2015-04-08 | 周广生 | Traditional Chinese medicinal composition for treating adhesive intestinal obstruction |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027515A (en) * | 2014-01-15 | 2014-09-10 | 朱峰 | Traditional Chinese medicine used for treating intestinal obstruction |
-
2018
- 2018-08-16 CN CN201810937922.3A patent/CN110833575B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785850A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional combination and preparation method thereof for intestinal obstruction treatment |
| CN104491381A (en) * | 2014-11-24 | 2015-04-08 | 周广生 | Traditional Chinese medicinal composition for treating adhesive intestinal obstruction |
Non-Patent Citations (2)
| Title |
|---|
| 吴茱萸外敷联合艾灸治疗小儿不完全性肠梗阻的疗效观察;黄小丽，等;《中国中医急症》;20171031;第26卷(第10期);第1846-1848页 * |
| 穴位贴敷疗法防治消化系统疾病经验体会;李依洁，等;《河北中医》;20160930;第38卷(第9期);第3.1小节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110833575A (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Research progress in the treatment of slow transit constipation by traditional Chinese medicine | |
| CN105902906A (en) | Traditional Chinese medicine composition for treating wind-cold-type cold and cough and preparation method thereof | |
| CN104383115A (en) | Traditional Chinese medicine preparation for treating coronary heart disease and preparation method of traditional Chinese medicine preparation | |
| CN103520680A (en) | Traditional Chinese medicine for treating acute heart failure | |
| CN110833575B (en) | A topical Chinese medicinal composition for the treatment of intestinal obstruction | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104127684B (en) | Traditional Chinese medicine compound preparation for treating cancers | |
| Lin et al. | Herb pairs containing Curcumae Rhizoma (Ezhu): A review of bio-active constituents, compatibility effects and t-copula function analysis | |
| CN105213726A (en) | A kind of Chinese medicine composition for the treatment of hemorrhoid | |
| CN110433271A (en) | A kind of pharmaceutical composition and its preparation method and application for treating functional dyspepsia FD | |
| CN103751650A (en) | Traditional Chinese medicinal composition for treating remission of gout and preparation method thereof | |
| CN107753800A (en) | A kind of Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN103301373A (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN105434808A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN107375636B (en) | Traditional Chinese medicine for treating impotence due to kidney deficiency and blood stasis and preparation method thereof | |
| CN111773342A (en) | Traditional Chinese medicine formula for treating chronic colorectal inflammation and auxiliary treating colorectal cancer | |
| CN106491992B (en) | A kind of blood-activating and stasis-removing composition and preparation method thereof | |
| CN105233087A (en) | Traditional Chinese medicine combination for being matched with chemotherapy for treating advanced large intestine cancer | |
| CN104940492A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN114939143A (en) | Navel patch and oral preparation for treating constipation after intestinal cancer surgery | |
| CN111388578A (en) | Traditional Chinese medicine composition for treating facial paralysis as well as preparation and application thereof | |
| CN111700858A (en) | Gel composition for treating cervical cancer and preparation method thereof | |
| CN104288282A (en) | Traditional Chinese medicinal composition for treating rheumatic arthritis and preparation method thereof | |
| CN110859923A (en) | Traditional Chinese medicine composition for treating haemorrhoids and preparation method and pharmaceutical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |